Baidu
map

Cancers:家族史和胃癌风险的关系:STOP研究的合并分析

2021-07-31 yd2015 MedSci原创

研究表明,有一代胃癌家族史可增加近2倍的发生胃癌风险,并且表明不同病理类型以及部位的风险不同,为以后的预防提供帮助。

虽然胃癌家族史(FH)与发生胃癌的风险有比较明确的相关性。但是对于病理类型,部位以及相关变量等仍需要进一步的明确。因此,国外研究团队开展了相关的研究,评估家族史(FH)与发生胃癌风险的关系。相关结果发表在Cancers杂志上。

该研究纳入STOP研究中的17项研究,共5946例胃癌患者以及12776例对照组。其中15.8%胃癌患者(n = 942) 以及7.7%对照组(n = 979)有一代亲属胃癌家族史。相对于对照组,胃癌患者中男性比例更高 (63.7% vs. 58.3%), ≥65岁患者更多(50.5% vs. 43.0%)以及更多的较低经济地位患者 (63.9% vs. 52.1%);同时,吸烟患者更多(28.9% vs. 25.8%),喝酒的患者更多(14.5% vs. 10.6%)。

与没有一代胃癌家族史相比,有一代胃癌家族史的胃癌发生风险增加,OR为1.84 (95% CI: 1.64–2.04; I2 = 6.1%, P heterogeneity = 0.383)。

         有或无家族史GC风险比

而分析不同家庭成员对发生胃癌风险影响时,有兄弟姐妹胃癌家族史的OR较父母胃癌家族史的高,分别为1.62 (95% CI = 1.20–2.05) 和1.54 (95% CI = 1.28–1.80)。没有观察到显著的异质性差异。

       兄弟姐妹或父母GC史的风险比

695例胃贲门GC患者中,92 (13.2%) 患者有一代GC家族史, 而3676例非胃贲门患者有648 (17.6%)例患者有一代GC家族史,合并ORs分别 为1.38 (95% CI = 0.98–1.77) 和1.82 (95% CI = 1.59–2.05)。

同样,2030 例肠型GC患者中, 365 (18.0%)例患者有一代GC家族史,OR 为1.92 (95% CI = 1.62–2.23);1170例弥漫型GC患者中,169 (14.4%)例患者有一代GC家族史,OR为1.62 (95% CI = 1.28–1.96)。

         亚组分析GC风险比

而对于年龄、吸烟史、经济地位、饮酒史、水果摄入、幽门螺杆菌感染等亚组分析没有统计学差异。

综上,研究表明,有一代胃癌家族史可增加近2倍的发生胃癌风险,并且表明不同病理类型以及部位的风险不同,为以后的预防提供帮助。

原始出处:

Vitelli-Storelli, F.; Rubín-García, M.; Pelucchi, C.;et al. Family History and Gastric Cancer Risk: A Pooled Investigation in the Stomach Cancer Pooling (STOP) Project Consortium. Cancers 2021, 13, 3844. https:// doi.org/10.3390/cancers13153844.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1820473, encodeId=015a18204e322, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Thu Aug 19 23:13:46 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878392, encodeId=78c918e8392b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Dec 21 03:13:46 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062027, encodeId=a4f4206202ecc, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Aug 11 04:13:46 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479819, encodeId=02a314e9819ea, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Mon Aug 02 05:13:46 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004246, encodeId=55531004246df, content=家族史影响好大, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65995533818, createdName=顿大侠, createdTime=Sat Jul 31 17:58:27 CST 2021, time=2021-07-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1820473, encodeId=015a18204e322, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Thu Aug 19 23:13:46 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878392, encodeId=78c918e8392b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Dec 21 03:13:46 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062027, encodeId=a4f4206202ecc, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Aug 11 04:13:46 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479819, encodeId=02a314e9819ea, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Mon Aug 02 05:13:46 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004246, encodeId=55531004246df, content=家族史影响好大, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65995533818, createdName=顿大侠, createdTime=Sat Jul 31 17:58:27 CST 2021, time=2021-07-31, status=1, ipAttribution=)]
    2021-12-21 anminleiryan
  3. [GetPortalCommentsPageByObjectIdResponse(id=1820473, encodeId=015a18204e322, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Thu Aug 19 23:13:46 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878392, encodeId=78c918e8392b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Dec 21 03:13:46 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062027, encodeId=a4f4206202ecc, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Aug 11 04:13:46 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479819, encodeId=02a314e9819ea, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Mon Aug 02 05:13:46 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004246, encodeId=55531004246df, content=家族史影响好大, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65995533818, createdName=顿大侠, createdTime=Sat Jul 31 17:58:27 CST 2021, time=2021-07-31, status=1, ipAttribution=)]
    2021-08-11 sjq027
  4. [GetPortalCommentsPageByObjectIdResponse(id=1820473, encodeId=015a18204e322, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Thu Aug 19 23:13:46 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878392, encodeId=78c918e8392b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Dec 21 03:13:46 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062027, encodeId=a4f4206202ecc, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Aug 11 04:13:46 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479819, encodeId=02a314e9819ea, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Mon Aug 02 05:13:46 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004246, encodeId=55531004246df, content=家族史影响好大, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65995533818, createdName=顿大侠, createdTime=Sat Jul 31 17:58:27 CST 2021, time=2021-07-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1820473, encodeId=015a18204e322, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Thu Aug 19 23:13:46 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878392, encodeId=78c918e8392b3, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Dec 21 03:13:46 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062027, encodeId=a4f4206202ecc, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Aug 11 04:13:46 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479819, encodeId=02a314e9819ea, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Mon Aug 02 05:13:46 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004246, encodeId=55531004246df, content=家族史影响好大, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65995533818, createdName=顿大侠, createdTime=Sat Jul 31 17:58:27 CST 2021, time=2021-07-31, status=1, ipAttribution=)]
    2021-07-31 顿大侠

    家族史影响好大

    0

相关资讯

胃癌早筛的手段有哪些?

胃癌早筛的手段有哪些?-实用教程——如何提高早期胃癌检出率?-

HP感染与胃癌的组织学类型有相关性吗?

HP感染与胃癌的组织学类型有相关性吗?-实用教程——如何提高早期胃癌检出率?问题7

胃癌哪种组织类型引起哪个临床症状比较多?

胃癌哪种组织类型引起哪个临床症状比较多?-实用教程——如何提高早期胃癌检出率?问题4

慢性萎缩性胃炎肠化生,轻度不典型增生如何治疗?

慢性萎缩性胃炎肠化生,轻度不典型增生如何治疗-实用教程——如何提高早期胃癌检出率?问题5.

JAMA Netw Open:全球胃癌发病率和死亡率数据来袭,东亚地区为重灾区!

在世界范围内,胃癌是最常见的癌症之一,每年新增患者超过100万,占所有癌症诊断的5.7%,且为大多数病例在诊断时已经发生转移,导致预后差生存率低。

胃黄色瘤和胃癌有什么联系?是否可以作为早期胃癌的一个报警信号?

胃黄色瘤和胃癌有什么联系?是否可以作为早期胃癌的一个报警信号?

Baidu
map
Baidu
map
Baidu
map